期刊文献+

头孢他啶杂质H研究 被引量:4

Study on ceftazidime impurity H
原文传递
导出
摘要 目的:对国产头孢他啶中共有的杂质H进行研究。方法:制备液相色谱采用Phenomenex Luna C18柱(150 mm×21.2 mm,5μm),流动相A为醋酸盐缓冲液(20 mmol·L-1醋酸铵,用醋酸调节pH为4.0),流动相B为乙腈,梯度洗脱,流速15 mL·min-1,柱温为室温。收集目标物冻干后利用紫外光谱、红外光谱、质谱、核磁共振对头孢他啶杂质H进行结构确认;并利用斑马鱼模式生物比较头孢他啶及其杂质H的胚胎发育毒性。结果:通过实验证实头孢他啶杂质H的结构为(6R,7R)-7-[[(2-氨基-1,3,4-噻唑-4-基)-2-(1-甲氧基2-甲基-1-氧代内烷-2-基)氧亚氨乙酰]氨基]-8-氧代-3-(吡啶-1-鎓-1-基-甲基)-5-硫杂-1-氮杂双环[4.2.0]辛-2-烯-2-甲酸;头孢他啶杂质H在斑马鱼胚胎毒性实验中的致畸作用是头孢他啶的25倍、致死作用是头孢他啶的8倍。结论:头孢他啶杂质H应予以严格控制。 Objective:To study the common impurity H in domestic ceftazidime. Methods:The HPLC system consisted of a Phenomenex Luna C18column( 150 mm × 21. 2 mm,5 μm),the mobile phase A was acetate buffer solution( 20 mmol·L1ammonium acetate,pH adjusted to 4. 0 with acetic acid),the mobile phase B was acetonitrile forgradient elution with the UV detector at 254 nm,the flow rate at 15 mL·min1,the column temperature at room temperature. The object was collected and freezedried. Ultraviolet spectrum,infrared spectrometry,mass spectrometry and nuclear magnetic resonance were adopted to confirm the chemical structure of ceftazidime impurity H. Thezebrafish was used as an ideal model to compare teratogenesis and toxicity between ceftazidime and impurity H.Results:The chemical structure of ceftazidime impurity H was confirmed to be( 6R,7R)7[[( 2Z)2-( 2-aminothiazol4yl)2-( 2methoxy1,1dimethyl2oxoethoxy) imino]acetyl]amino]8oxo3-[( 1-pyridinio) methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate. Ceftazidime impurity H was 25 times higher in teratogenesis and 8times higher in toxicity compared with ceftazidime in zebrafishembryo toxicity test. Conclusion:Ceftazidime impurity H should be controlled strictly.
出处 《药物分析杂志》 CAS CSCD 北大核心 2014年第9期1605-1610,共6页 Chinese Journal of Pharmaceutical Analysis
基金 十二五国家科技重大专项"重大新药创制"课题"化学新药质量标准研究与评价技术平台"之"化学原料药"子课题(2011-ZX09303-001)
关键词 头孢他啶 杂质H鉴定 制备液相色谱 紫外光谱 红外光谱 核磁共振 质谱 斑马鱼胚胎毒性实验 致畸作用 ceftazidime identification of impurity H preparative liquid chromatography UV IR NMR MS zebrafish embryo loxicity test teratogenicity
  • 相关文献

参考文献14

  • 1ChP 2010.Vol Ⅱ(中国药典2010年版.二部)[S].2010:678.
  • 2EP 8.0[S].2014:1811.
  • 3USP 36-NF 31[S].2013:2886.
  • 4Ferdosian F,Ghiliyan R,Hashemi A,et al.Comparing the efficacy of ceftazidime and meropenem in treatment of febrile neutropenia in pediatric patients with cancer[J].Iran J Ped Hematol Oncol,2013,3(3):103.
  • 5Richards DM,Brogden RN.Ceftazidime.A review of its antibacterial activity,pharmacokinetic properties and therapeutic use[J].Drugs,1985,29(2):105.
  • 6Sader HS,Castanheira M,Flamm RK,et al.Antimicrobial activity of ceftazidime-avibactam against gram-negative organisms collected from U.S.Medical Centers in 2012[J].Antimicrob Agents Chemother,2014,58(3):1684.
  • 7Meyers BR.Comparative toxicities of third-generation cephalosporins[J].Am J Med,1985,79(2A):96.
  • 8Foord RD.Ceftazidime:aspects of efficacy and tolerance[J].J Antimicrob Chemother,1983,12(Suppl A):399.
  • 9Picard M,Fernandez MI,Des Roches A,et al.Ceftazidime-induced drug reaction with eosinophilia and systemic symptoms(DRESS)complicated by hemophagocytic lymphohistiocytosis[J].J Allergy Clin Immunol Pract,2013,1(4):409.
  • 10State Food and Drug Administration(国家食品药品监督管理局).2012 Annual Report of Adverse Drug Reactions(ADR)Monitoring(2012年药品不良反应检测年度报告)[EB/OL].2013-03-14[2013-7-18]http://www.sda.gov.cn/WS01/CL0051/79058.html.

二级参考文献22

共引文献41

同被引文献74

引证文献4

二级引证文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部